Plain-English translation of NCT06243588 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a research study that looks back at the medical records of patients with Ewing sarcoma (a type of bone cancer) who were treated at Rizzoli Institute between 1991 and 2021. Researchers want to understand which factors — like a patient's age, tumor size, location, and response to chemotherapy — help predict who will do better or worse after treatment. By identifying these patterns, doctors hope to spot high-risk patients earlier and give them more personalized care.
Currently, doctors don't have a clear way to predict which patients with this bone cancer will have the best or worst outcomes. This study aims to fill that gap by analyzing decades of patient data, so that in the future, doctors can offer tailored treatment plans and follow-up care to patients who need it most.
You likely qualify if…
You likely don't qualify if…
This study does not involve any new treatments or visits. Researchers will simply review your existing medical and imaging records from your care at Rizzoli Institute to gather information about your diagnosis, treatment, and long-term outcomes. No additional blood tests, scans, or appointments are required — it is purely a review of your past medical information.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
Italy
Enrollment target
~400 participants
Started
January 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
2 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Costantino Errani
Istituto Ortopedico Rizzoli
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.